Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1

Gorny, Miroslaw K.; Wang, Xiaohong; Williams, Constance; Volsky, Barbara; Revesz, Kathy; Witover, Bradley; Burda, Sherri; Urbanski, Mateusz M.; Nyambi, Phillipe N.; Krachmarov, Chavdar; Pinter, Abraham; Zolla‐Pazner, Susan; Nádas, Arthur

doi:10.1016/j.molimm.2008.09.005

Cited by 94 publications

(120 citation statements)

References 60 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Although there is no direct evidence of such a mechanism, several recent studies indicate the presence of repertoire-based regulatory mechanisms in circulating B-cell subsets. Despite the tendency of pathogen-specific antibody responses to exhibit biased germline gene repertoires, [16][17][18] the frequency of gene family use in naïve and memory subsets is remarkably consistent across individuals. 9,11 Further, alteration of this gene family homeostasis in the circulating B-cell repertoire is associated with disease states.…”

Section: Resultsmentioning

confidence: 98%

High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals

et al. 2012

View full text Add to dashboard Cite

Vast diversity in the antibody repertoire is a key component of the adaptive immune response. This diversity is generated centrally through the assembly of variable, diversity and joining gene segments, and peripherally by somatic hypermutation and class-switch recombination. The peripheral diversification process is thought to only occur in response to antigenic stimulus, producing antigenselected memory B cells. Surprisingly, analyses of the variable, diversity and joining gene segments have revealed that the naïve and memory subsets are composed of similar proportions of these elements. Lacking, however, is a more detailed study, analyzing the repertoires of naïve and memory subsets at the level of the complete V(D)J recombinant. This report presents a thorough examination of V(D)J recombinants in the human peripheral blood repertoire, revealing surprisingly large repertoire differences between circulating B-cell subsets and providing genetic evidence for global control of repertoire diversity in naïve and memory circulating B-cell subsets.

show abstract

Section: Resultsmentioning

confidence: 98%

High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Bu kapsamda kullanılan heteromiyeloma hücreleri, belirli bir insan hücre hattı (sıklıkla miyeloma hücreleri) ile fare miyeloma hücrelerinin füzyonu sonucunda elde edilmektedir 19 . Bu kapsamda yapılan çalışmalarda geliştirilen heteromiyeloma hücre hatlarında insan kökenli partner olarak insan miyeloma hücre hatlarının yanı sıra [22][23][24][25] , IgA miyeloma hastası bireyden izole edilen kemik iliği mononükleer © Kocaeli Üniversitesi Sağlık Bilimleri Dergisi, 2016 SBD16-1.2 SBD 2016 S.1, C.2, s.6-14…”

Section: Kaynaklarunclassified

Monoklonal Antikor Teknolojisinin Dünü, Bugünü Ve Geleceği

Selimoglu¹,

Kasap²,

Akpınar³

et al. 2016

Kocaeli Üniversitesi Sağlık Bilimleri Dergisi

View full text Add to dashboard Cite

When Paul Erlich postulated the idea of "magic bullet" in the early part of 20th century, he only had the findings of a research, regarding the presence of humoral immunity, performed by Emil von Behring and Kitasato Shibasaburo.. There was no concrete data about the presence of antibodies in those days. According to the idea, "if a compound could be made that selectively targeted a disease-causing organism, then a toxin for that organism could be delivered along with the agent of selectivity". If the point in the technology of monoclonal antibody generation that we have reached from '80s to present is considered, it can be claimed that we have started to go beyond the technology realizing the fighting strategy principally proposed by Paul Erlich at those times. The period starting with the production of fully murine antibodies in the first years exhibited a fast-growing trend with the help of recombinant

show abstract

“…SHM-D33 was generated by fusing the mouse myeloma cell line P3X63Ag8 with human myeloma cell line FU-266 (62). This fusion partner has been used very successfully to generate large panels of naturally occurring human anti-HIV mAbs (63)(64)(65). Another heterohybridoma fusion partner that has been very productive is HMMA 2.5 (66), which was generated using a multistep process.…”

Section: Fusion Partnersmentioning

confidence: 99%

Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies

Smith

Crowe

2015

Microbiol Spectr

View full text Add to dashboard Cite

The human hybridoma technique offers an important approach for isolation of human monoclonal antibodies. A diversity of approaches can be used with varying success. Recent technical advances in expanding the starting number of human antigen-specific B cells, improving fusion efficiency, and isolating new myeloma partners and new cell cloning methods have enabled the development of protocols that make the isolation of human monoclonal antibodies from blood samples feasible. Undoubtedly, additional innovations that could improve efficiency are possible. HISTORY OF HYBRIDOMASMonoclonal antibodies (mAbs) have revolutionized the conduct of science since their first description in 1975 (1). The use of these specific reagents also has made possible improved clinical diagnostics in the medical arena, and many antibodies have found their way to clinical use as prophylactic or therapeutic agents. Nevertheless, the potential of mAbs derived specifically from technology based on human hybridomas remains largely unfulfilled. The principal reason for the lack of a large number of hybridoma-derived mAb therapeutics has simply been the technical difficulty in generating stable hybridomas that secrete human mAbs of high affinity and functional activity. This chapter reviews recent efforts to develop and employ novel methods for the efficient generation of human hybridomas secreting human mAbs for clinical use.The principal advantage of the use of human hybridoma technology for mAb generation is that this approach preserves the authentic sequence and pairing of antibody DNA from a natural B cell for the expression of a naturally occurring full-length human mAb. There are significant theoretical advantages for expressing cDNAs encoding authentic heavy and light chains with chains that are paired using the coding sequence as it was generated naturally through B cell selection, class switch, and affinity maturation. No genetic modification of these sequences is required. Since antibody expression is typically very stable in hybridomas, sequence amplification of antibody variable genes is achieved easily if recombinant production or manipulation is desired. The resulting recombinant mAb retains most features of naturally occurring human antibodies, as the clone retains the native amino acid sequence and heavy/light chain pairing. Since the native constant region of the antibody in the original human B cell is retained in the mAb expressed by the resulting hybridoma, the functional properties of the particular Fc region can be studied for Fc-mediated activities, such as antibodydependent cellular cytotoxicity.

show abstract

Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1

Cited by 94 publications

References 60 publications

High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals

High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals

Monoklonal Antikor Teknolojisinin Dünü, Bugünü Ve Geleceği

Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies

Contact Info

Product

Resources

About